# A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation

> **NCT07174908** · PHASE3 · RECRUITING · sponsor: **InxMed (Shanghai) Co., Ltd.** · enrollment: 400 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** IN10018 in combination with D-1553
- **DRUG:** anti-PD-1 monoclonal antibody in combination with platinum and pemetrexed

## Key facts

- **NCT ID:** NCT07174908
- **Lead sponsor:** InxMed (Shanghai) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-10
- **Primary completion:** 2028-09
- **Final completion:** 2030-09
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2026-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07174908

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07174908, "A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07174908. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*